NOTICE

Notice is hereby given that the 48th Annual General Meeting of the Members of Gland Pharma Limited will be held on Tuesday, August 25, 2026, at 11.00 A.M (IST) through video conferencing (VC) / other audio-visual means (OAVM) to transact the following business:

Ordinary Business(es):

1. To receive, consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2026 including the Audited Balance Sheet as at 31st March, 2026; the Statement of Profit and Loss, Statement of changes in Equity and the Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto, together with the Reports of the Board of Directors and Auditors thereon.

   "RESOLVED THAT the audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2026 including the Audited Balance Sheet as at 31st March, 2026; the Statement of Profit and Loss, the Statement of changes in Equity and the Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto and the reports of the Board of Directors and Auditors thereon as circulated to the Members with the Notice of the Annual General Meeting and submitted to this Meeting be and are hereby, considered and adopted."

2. To receive, consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2026 including the Audited Consolidated Balance Sheet as at 31st March, 2026; the Consolidated Statement of Profit and Loss, Consolidated Statement of changes in Equity and the Consolidated Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto, together with the Report of the Auditors thereon.

   "RESOLVED THAT the audited Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2026 including the Audited Consolidated Balance sheet as at 31st March, 2026; the Consolidated Statement of Profit and Loss, the Consolidated Statement of changes in Equity and the Consolidated Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto and the report of Auditors thereon as circulated to the Members with the Notice of the Annual General Meeting and submitted to this Meeting be and are hereby considered and adopted."

3. To declare the final dividend on equity shares for the financial year ended 31st March 2026.

   "RESOLVED THAT a final dividend of ₹ 20/- (INR Twenty only) per equity share of face value ₹ 1/-, each fully paid-up of the Company, as recommended by the Board of Directors of the Company for the Financial year ended March 31, 2026 on paid-up capital of ₹ 164,959,682 or such other paid-up capital of the Company as may be outstanding as on the Record Date, be and is hereby declared and the same be paid out of the profits of the Company within the stipulated timelines to the eligible shareholders of the Company whose names appear on the Register of Members of the Company as on the Record date i.e., Tuesday, August 11, 2026."

4. To reappoint Mr. Wenjie Zhang as a Director, liable to retire by rotation and being eligible offers himself for reappointment.

   "RESOLVED THAT pursuant to Section 152 and other applicable provisions of the Companies Act, 2013; Mr. Wenjie Zhang (DIN: 10727581), who retires by rotation and being eligible offers himself for re-appointment, be and is hereby re-appointed as a director of the Company liable to retire by rotation."

5. To reappoint Ms. Wei Huang as a Director, liable to retire by rotation and being eligible offers herself for reappointment.

   "RESOLVED THAT pursuant to Section 152 and other applicable provisions of the Companies Act, 2013; Ms. Wei Huang (DIN: 10818586), who retires by rotation and being eligible offers herself for re-appointment, be and is hereby re-appointed as a director of the Company liable to retire by rotation."

By Order of the Board of Directors

Sampath Kumar Pallerlamudi
Company Secretary
Membership No. A17901

Place: Hyderabad
Date: 15.06.2026

Registered Office Address:
Gland Pharma Limited
Survey No. 143-148, 150 & 151
Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal - Gandimaisamma Mandal
Medchal-Malkajgiri District
Hyderabad 500 043, Telangana, India
CIN: L24239TG1978PLC002276
Tel: 040-30510999, Fax:040-30510800
Email:gland@glandpharma.com
Website: https://glandpharma.com/

Notes:

1) The relevant details, pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) and Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India, in respect of Directors seeking re-appointment or continuation at this AGM are annexed.

2) Pursuant to General Circulars No. 14/2020 dated April 8, 2020; No. 17/2020 dated April 13, 2020; No. 22/2020 dated June 15, 2020; No. 33/2020 dated September 28, 2020; No. 39/2020 dated December 31, 2020; No. 02/2021 dated January 13, 2021; No. 10/2021 dated June 23, 2021; No.20/2021 dated December 8, 2021; No. 3/2022 dated May 5, 2022, No.11/2022 dated December 28, 2022; No. 09/2023 dated September 25, 2023; No. 09/2024 dated September 19, 2024 and No. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs (hereinafter referred to as "MCA Circulars") and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as "Listing Regulations"); companies are permitted to hold the AGM through VC/OAVM, without the physical presence of the members at a common venue. Accordingly, the 48th AGM of the Company will be convened through VC/OAVM in compliance with the provisions of the Companies Act, 2013 and Rules made thereunder, Listing Regulations read with the aforesaid Circulars. The deemed venue for the 48th AGM shall be the Corporate Office of the Company i.e., Plot No.11& 84, TSIIC, Phase-IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad 502 307, Telangana.

3) In accordance with the applicable Circulars, the Company is providing VC/OAVM to its Members to attend the 48th AGM. The facility for attending the AGM virtually will be made available for 1000 members on a first-come-first-served basis. However, please note that pursuant to the applicable Circulars, large shareholders (i.e., shareholders holding 2% or more shareholding), promoters, institutional investors, directors, key managerial personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee, Stakeholders' Relationship Committee and Share Transfer Committee, auditors, etc. may be allowed to attend the Meeting without restriction on account of first-come-first-served principle.

4) The VC/OAVM facility for members to join the Meeting shall be kept open 30 minutes before the start of the AGM and shall be closed on expiry of 30 minutes after the conclusion of the AGM. Members can attend the AGM through VC/OAVM by following the instructions mentioned in this Notice.

5) The facility for appointment of proxies by members is not available as the AGM will be held through VC/OAVM and physical attendance of the members is dispensed with pursuant to the aforesaid Circulars. Hence, the route map, proxy form and attendance slip are not annexed to this Notice.

6) Institutional/Corporate members whose authorized representatives are intending to attend the Meeting are requested to send to the Company at investors@glandpharma.com, a certified copy of the board resolution / Power of Attorney/Authority Letter, etc. authorizing such representative to attend the AGM through VC/OAVM, and cast their votes through e-voting.

7) Members attending the AGM through VC/OAVM shall be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.

8) The statutory registers including the Register of Directors and Key Managerial Personnel and their Shareholding, the Register of Contracts or Arrangements in which Directors are interested, maintained under the Companies Act, 2013 and all other documents referred to in the Notice will be available for inspection in electronic mode. Members who wish to inspect the register are requested to write to the Company by sending e-mail to investors@glandpharma.com.

9) In accordance with the aforesaid Circulars, the Notice of the 48th AGM along with the Annual Report for the financial year ended March 31, 2026, is being sent only through electronic mode to those members who have registered their e-mail addresses with the Company/Depository Participants. Members may note that the Notice of the 48th AGM and the Annual Report are also available on the Company's website: www.glandpharma.com. The Notice of AGM and Annual Report will also be available on website of NSDL (www.evoting.nsdl.com) and on the website of Stock Exchanges (www.bseindia.com) and (www.nseindia.com).

10) In accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024, no physical copy of the Notice of the 48th AGM and the Annual Report for the financial year 2025-26 will be sent to members who have not registered their e-mail addresses with the Company/Depositories/RTA/ Depository Participants, instead a letter containing a web-link along with QR Code, including the path where complete details of the Annual Report for the Financial Year 2025-26 are available will be sent to those shareholders

11) In accordance with the Circulars, members who have not registered their e-mail address may register their e-mail address with their Depository Participant or send their consent at investors@glandpharma.com or rnt.helpdesk@in.mpms.mufg.com along with their Folio No./DP ID Client ID and valid e-mail address for registration.

12) Pursuant to Section 108 of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended from time to time, Regulation 44 of the Listing Regulations and the aforesaid Circulars, the Company is pleased to offer voting by electronic means to the members to cast their votes electronically on all resolutions set forth in this Notice. The detailed instructions for e-voting and attending the AGM through VC/OAVM are given as a separate attachment to this Notice.

13) Members, desiring any information relating to the financials from the Management or the Statutory Auditors, are requested to write to the Company at investors@glandpharma.com at an early date.

14) A certificate from the Secretarial Auditors of the Company certifying that the Company's 'Gland Pharma Employees Stock Option Scheme, 2019' and 'Gland Pharma Employee Stock Option Scheme, 2025' are being implemented in accordance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 is required to be placed at the AGM. Such Certificate will be available for inspection by the members in electronic mode before and during the AGM. Members who wish to inspect the certificate are requested to write to the Company by sending an e-mail to investors@glandpharma.com.

15) Members are requested to intimate immediately, any change in their address to their Depository Participants with whom they are maintaining their Demat accounts. If the shares are held in physical form, change in address has to be intimated to the Company's Registrar and Transfer Agent (RTA), MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited), C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai – 400 083, Maharashtra, India. Tel : +91- 810 811 6767, e-mail ID: rnt.helpdesk@in.mpms.mufg.com

16) SEBI has mandated the submission of permanent account number (PAN) by every participant in securities market. Members holding shares in electronic form are, therefore, requested to submit their PAN to their depository participants with whom they are maintaining their Demat accounts. Members holding shares in physical form should submit their PAN to the Company or its RTA.

17) SEBI vide its Circular dated November 3, 2021 has mandated registration of PAN, KYC details and Nomination, by holders of physical securities. Members holding shares in physical form are requested to submit their PAN, KYC details and Nomination details by sending Form ISR-1 and/ or related documents mentioned therein to the RTA. The formats for choice of Nomination and Updation of KYC details viz; Forms ISR-1, ISR-2, ISR-3, SH-13, SH-14 and SEBI circulars are available on our RTA's website at https://www.in.mpms.mufg.com > Resources > Downloads > KYC > Formats for KYC.

18) Regulation 40 of the Listing Regulations, as amended, mandates that transfer, transmission and transposition of securities of listed companies held in physical form shall be affected only in demat mode. Further, SEBI, vide its Circular dated January 25, 2022, has clarified that listed companies, with immediate effect shall issue the securities only in demat mode while processing investor service requests pertaining to the issuance of duplicate shares, exchange of shares, endorsement, sub-division/ consolidation of share certificates, etc. In view of this and also to eliminate all risks associated with physical shares and for ease of portfolio management, members holding shares in physical form are requested to consider converting their holdings to demat mode.

19) Your Company is pleased to provide the facility of live webcast of proceedings of AGM. Members who are entitled to participate in the AGM can view the live proceedings of AGM by logging on the NSDL website at https://www.evoting.nsdl.com/, using their secure login credentials. Members are encouraged to use this facility of the live webcast. The webcast facility will be available from AGM start time i.e., 11:00 A.M. (IST) onwards on Tuesday, August 25, 2026.

20) The Board of Directors of the Company has appointed Ms. D Soumya, Associate Partner, RVR & Associates, Practicing Company Secretary (Membership No.F11754; Certificate of practice no. 13199) as the Scrutinizer to scrutinize the remote electronic voting ("e-voting") process and e-voting in a fair and transparent manner.

21. At the AGM, at the end of discussion on the resolutions on which voting is to be held, the Chairman shall, with the assistance of scrutinizer, order voting through

electronic means for all those members who are present at the AGM through VC/OAVM but have not cast their votes electronically using the remote e-voting facility.

22. Immediately after the conclusion of voting at the AGM, the scrutinizer shall first count the votes cast at the AGM and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company. The scrutinizer shall prepare a consolidated scrutinizer's report of the total votes cast in favor or against, if any, not later than two working days after the conclusion of the AGM. This report shall be made to the Chairman, or any other person authorized by the Chairman, who shall declare the result of the voting forthwith.

23. The voting results declared along with the scrutinizer's report shall be placed on the Company's website www.glandpharma.com and on the NSDL website www.evoting.nsdl.com immediately after the declaration of the result by the Chairman or a person authorized by the Chairman. The results shall also be immediately forwarded to the BSE Limited, and National Stock Exchange of India Limited.

24) Members are hereby informed that for addressing the unresolved disputes pertaining to or emanating from investor services between listed company / RTAs offering services on behalf of the listed company and its shareholders, SEBI vide circular dated May 30, 2022 read with Circular dated April 8, 2022, introduced Standard Operating Procedure to be followed under the Stock Exchange arbitration process. The mechanism can be initiated only post exhausting all actions for resolution of complaints including those received through the SCORES portal.

By Order of the Board of Directors

Sampath Kumar Pallerlamudi
Company Secretary
Membership No. A17901

Place: Hyderabad
Date: 15.06.2026

Registered Office Address:

Gland Pharma Limited
Survey No. 143-148, 150 & 151
Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal - Gandimaisamma Mandal
Medchal-Malkajgiri District
Hyderabad 500 043, Telangana, India
CIN: L24239TG1978PLC002276
Tel: 040-30510999, Fax:040-30510800
Email: gland@glandpharma.com
Website: https://glandpharma.com/

DETAILS OF THE DIRECTORS PROPOSED TO BE APPOINTED / RE-APPOINTED, AS REQUIRED UNDER REGULATION 36(3) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (LISTING REGULATIONS) AND SECRETARIAL STANDARD ON GENERAL MEETINGS (SS-2) (ITEM NO. 4 AND 5)

ITEM NO. 4:

To reappoint Mr. Wenjie Zhang as a Director, liable to retire by rotation and being eligible, offers himself for reappointment.

Mr. Wenjie Zhang is a Non-Executive and Non-Independent Director of the Company. Mr. Wenjie Zhang is currently the Co-President and Co-CEO of Innovative Medicines division of Fosun Pharma. He is also the Chairman and Non-Executive Director of Shanghai Henlius Biotech Co. Ltd and Chairman of Fosun Kairos (Shanghai) Biological Technology Co., Ltd. (formerly known as Fosun Kite Biological Technology Co., Ltd.). Mr. Wenjie Zhang joined Fosun Pharma Group and served as Senior Vice President, Chief Commercial Operations Officer, Chief Strategic Officer, President, CEO, and Chairman of Shanghai Henlius Biotech Co., Ltd. since March, 2019. Before joining Henlius in March, 2019; Mr. Zhang served as General Manager of Amgen China and also worked as Vice President, Oncology for Roche China from 2010 to 2014. Mr. Zhang holds an MBA degree from Yale University School of Management and a B.S. degree in Microbiology from Shandong University.

He was first appointed on the Board of Directors of the Company on August 30, 2024. He is presently Non-Executive and Non-Independent Director of the Company and a Member of the Stakeholders Relationship Committee & Share Transfer Committee (appointed w.e.f. November 04, 2024) of the Board of Directors of the Company. He retires by rotation at the 48th AGM of the Company, and being eligible, offers himself for reappointment. The Company has received an intimation in form DIR-8 pursuant to Rule 14 of the Companies (Appointment and Qualification of Directors) Rules, 2014; from Mr. Wenjie Zhang to the effect that he is not disqualified in accordance with Section 164(2) of the Companies Act, 2013 and a declaration that he is not debarred or restrained from acting as a director by any order of SEBI or by any such other Authority. Mr. Wenjie Zhang is neither a director in any of the listed companies nor resigned from any listed company during past three years in India. As he is a Non- Executive Director of the Company, he does not draw any remuneration from the Company.

Mr. Wenjie Zhang has attended Three (3) out of Six (6) Board meetings and One (1) out of Three (3) Stakeholders Relationship Committee & Share Transfer Committee meetings held during the FY 2025-26. He does not hold any equity shares in the Company and is not related to any Director /Key Managerial Personnel of the Company.

Except Mr. Wenjie Zhang, none of the other directors or key managerial personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the resolution set out at item No. 4 of the Notice. The Board recommends the resolution set forth in item No. 4 of the Notice for approval of the Members.

ITEM NO. 5:

To reappoint Ms. Wei Huang as a Director, liable to retire by rotation and being eligible, offers herself for reappointment.

Ms. Wei Huang is a Non-Executive and Non-Independent Director of the Company. She is currently the President of Shanghai Henlius Biotech Inc., responsible for the production and supply of the Company's clinical and commercial products, design and implementation of engineering projects, continuous improvement and optimization of production capacity. She is also a Director of Shanghai Henlius Bioscience Co., Ltd. Ms. Wei Huang has leadership experience in pharmaceutical and biotechnology industry spanning over 32 years in process development, technology transfer, manufacturing, process and facility design, capital project execution, and quality system implementation. She joined Fosun Pharma Group and served as Senior Vice President, Chief Operating Officer, and President of Shanghai Henlius Biotech Inc. since Dec. 2019. Prior to that, Ms. Huang served as Chief Adviser of NEWA Technology Inc., responsible for areas such as project management, manufacturing, validation, process development and CMC, cGMP compliance audits, techno-economic assessment, gap and risk mitigation, and strategic guidance for the company. Prior to NEWA, Ms. Huang, during 2008-2013 served as Vice-President of Process Development and Engineering of REG Life Sciences Corporation. Ms. Huang holds Master's degree from University of Maryland in Chemical and Biochemical Engineering and Bachelor's degree from East China University of Science and Technology in Biochemical Engineering.

Ms. Wei Huang has been appointed as an Additional Director on the Board of the Company on November 04, 2024 and the shareholders of the Company have approved her appointment as a Non-Executive Director vide resolution passed through postal ballot dated December 08, 2024. She is a member of the Nomination and Remuneration Committee of the Board of Directors.

She retires by rotation at the 48th AGM of the Company, and being eligible, offers herself for reappointment.

The Company has received an intimation in form DIR-8 pursuant to Rule 14 of the Companies (Appointment and Qualification of Directors) Rules, 2014; from Ms. Wei Huang to the effect that she is not disqualified in accordance with Section 164(2) of the Companies Act, 2013 and a declaration that she is not debarred or restrained from acting as a director by any SEBI order or by any other such authority.

Ms. Wei Huang is neither a director in any of the Indian listed Companies nor resigned from any Indian Listed Company during the past three years. As she is a Non-Executive Director of the Company, she does not draw any remuneration from the Company.

Ms. Wei Huang has attended three out of Six (6) Board meetings and one out of Four (4) Nomination & Remuneration Committee meetings held during the FY 2025-26. She does not hold any equity shares in the Company and is not related to any Director /Key Managerial Personnel of the Company.

Except Ms. Wei Huang, none of the other directors or key managerial personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the resolution set out in item No. 5 of the Notice. The Board recommends the resolution set forth in item No. 5 of the Notice for approval of the members.

The details as required under Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard - 2 on General Meetings and other provisions of applicable laws are provided in **Annexure –I**.

By Order of the Board of Directors

Sampath Kumar Pallerlamudi
Company Secretary
Membership No. A17901

Place: Hyderabad
Date: 15.06.2026

Registered Office Address:
Gland Pharma Limited
Survey No. 143-148, 150 & 151
Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal - Gandimaisamma Mandal
Medchal-Malkajgiri District
Hyderabad 500 043, Telangana, India
CIN: L24239TG1978PLC002276
Tel: 040-30510999, Fax:040-30510800
Email:gland@glandpharma.com
Website: https://glandpharma.com/

Annexure-I

Details of the Directors proposed to be appointed / re-appointed as required under Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings are as given below:

(A)

Name	Mr. Wenjie Zhang
DIN	10727581
Age	59 Years (Date of Birth – February 10, 1967)
Qualification	• Bachelor's degree in Microbiology from Shandong University. • Master's degree in Business Administration from Yale University School of Management
Experience (including expertise in specific functional area)/ Brief Resume	As mentioned in the details of the Directors proposed to be appointed or reappointed of Item No. 4
Terms and Conditions of continuation	As per the resolution at Item No.4 of the Notice of the 48th Annual General Meeting
Remuneration last drawn (including sitting fees, if any)	Mr. Wenjie Zhang is a Non- Executive Director of the Company. He does not draw any remuneration from the Company.
Remuneration proposed to be paid	Not applicable
Date of first appointment on the Board	He was first appointed on the Board on August 30, 2024
Shareholding in the Company as on the date of Notice (including shareholding as a beneficial owner)	Nil
Relationship with other Directors/Key Managerial Personnel	Not related to any Director /Key Managerial Personnel
Number of meetings of the Board attended during the year (FY 2025-26)	3 (Total 6 Board Meetings were held in FY 2025-26)
Chairpersonship/Membership of the Committee(s) of the Board of Directors of the Company as on the date of Notice	Member of the Stakeholders' Relationship Committee & Share Transfer Committee Mr. Wenjie Zhang is not acting as Chairman for any of the Committees of the Board of Directors of the Company
Other companies in which he is a Director excluding Directorship in Private and Section 8 companies as on date of Notice (including listed entities from which he has resigned in the past three years)	Nil
Chairpersonship/ Membership of the Committee(s) of Board of Directors of other companies in which he is a Director excluding Private and Section 8 companies as on date of Notice (including listed entities from which the person has resigned in the past three years)	Nil

(B)

Name	Ms. Wei Huang
DIN	10818586
Age	58 Years (Date of Birth – October 16, 1967)
Qualification	• Master's degree in Chemical and Biochemical Engineering from University of Maryland • Bachelor's degree in Biochemical Engineering from East China University of Science and Technology
Experience (including expertise in specific functional area)/ Brief Resume	As mentioned in the details of the Directors proposed to be appointed or reappointed of Item No. 5
Terms and Conditions of Reappointment	As per the resolution at Item No.5 of the Notice of the 48th Annual General Meeting.
Remuneration last drawn (including sitting fees, if any)	Ms. Wei Huang is a Non- Executive Director of the Company. She does not draw any remuneration from the Company.
Remuneration proposed to be paid	Not applicable
Date of first appointment on the Board	Ms. Wei Huang has been appointed as an Additional Director on the Board of the Company on November 04, 2024 and the shareholders of the Company have approved her appointment as a Non-Executive Director vide resolution passed through postal ballot dated December 08, 2024
Shareholding in the Company as on the date of Notice (including shareholding as a beneficial owner)	Nil
Relationship with other Directors/Key Managerial Personnel	Not related to any Director /Key Managerial Personnel
Number of meetings of the Board attended during the year (FY 2025-26)	3 (Total 6 Board Meetings were held in FY 2025-26)
Chairpersonship/Membership of the Committee(s) of the Board of Directors of the Company as on the date of Notice	Member of the Nomination & Remuneration Committee. Ms. Wei Huang is not acting as Chairman for any of the Committees of the Board of the Directors of the Company
Other companies in which she is a Director excluding Directorship in Private and Section 8 companies as on date of Notice (including listed entities from which she has resigned in the past three years)	Nil
Chairpersonship/ Membership of the Committee(s) of Board of Directors of other companies in which she is a Director excluding Private and Section 8 companies as on date of Notice (including listed entities from which she has resigned in the past three years)	Nil

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER:-

Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) the Secret arial Standard on General Meetings (SS-2) issued by the ICSI and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs from time to time the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as e-voting on the date of the AGM will be provided by NSDL.

The remote e-voting facility is available at the following link: https://www.evoting.nsdl.com/

The e-voting event number (EVEN) and period of remote e-voting are set out below:

EVEN	Commencement of remote e-voting	End of remote e-voting
140557	Saturday, August 22, 2026 at 09:00 A.M.	Monday, August 24, 2026 at 05:00 P.M.

The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. **August 18, 2026** may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being August 18, 2026.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) **Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode**

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. Existing **IDeAS** user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "**Beneficial Owner**" icon under "**Login**" which is available under '**IDeAS**' section , this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "**Access to e-Voting**" under e-Voting services and you will be able to see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "**Register Online for IDeAS Portal**" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 5. Shareholders/Members can also download NSDL Mobile App "**NSDL Speede**" facility by scanning the QR code mentioned below for seamless voting experience. **NSDL Mobile App is available on** App Store Google Play

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with CDSL	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) **Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.**

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.

2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.

3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen. Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:

   a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.

   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.

   c) How to retrieve your 'initial password'?

      (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.

      (ii) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:

   a) Click on "**Forgot User Details/Password?**"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.

   b) **Physical User Reset Password?**" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.

   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.

   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.

8. Now, you will have to click on "Login" button.

9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/ OAVM" link placed under "Join Meeting".
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/ JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to mail@csrvrassociates.com with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 or send a request to Mr. Swapneel Puppala at evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to Investors@glandpharma.com
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to (Investors@glandpharma.com). If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A)** i.e.

   Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.
3. Alternatively shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE EGM/AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the EGM/ AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the EGM/AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the EGM/AGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the EGM/AGM. However, they will not be eligible to vote at the EGM/AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the EGM/AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for Access to NSDL e-Voting system. After successful login, you can see link of "VC/OAVM" placed under "Join meeting" menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

2. Members are encouraged to join the Meeting through Laptops for better experience.

3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

5. Shareholders who would like to express their views/ have questions may send their questions in advance mentioning their name demat account number/ folio number, email id, mobile number at (Investors@glandpharma.com). The same will be replied by the company suitably.

6. **Instructions for Shareholders/ Members to Speak during the Annual General Meeting:**
   - Shareholders who would like to speak during the meeting must register their request with the company.
   - Shareholders will get confirmation on first cum first basis depending upon the provision made by the Company.
   - Shareholders will receive "speaking serial number" once they mark attendance for the meeting.
   - Other shareholders may ask questions to the panelist via active chat-board during the meeting.
   - Please remember speaking serial number and start your conversation with panelist by switching on video mode and audio of your device.
   - Shareholders are requested to speak only when moderator of the meeting/ management will announce the name and serial number for speaking.

7. **Instructions for Income Tax compliance with respect to dividend:**

   i. The Board of Directors had recommended a Final Dividend of ₹ 20/- (2000%) per equity share of face value of ₹ 1/- each for the Financial Year ended March 31, 2026, subject to approval of the Members at the ensuing AGM. If the final dividend, as recommended by the Board of Directors, is approved at the AGM, payment of such dividend subject to deduction of tax at source will be made within thirty days of receipt of shareholders' approval.

   ii. The record date for the purpose of determining the eligibility of shareholders to receive the Final Dividend, if approved by shareholders in the ensuing AGM is August 11, 2026.

   iii. With effect from April 01, 2024, as per the SEBI Circular dated June 10, 2024 read with SEBI Master Circular dated May 07, 2024, shareholders holding shares in physical form and who have not completed any of their KYC, will be eligible to receive dividend, only upon completion of KYC. Members are therefore advised to update their KYC details on priority, if not done already by following the procedure as mentioned below:

   - Shareholders who are holding shares in physical mode and have not registered or updated their email IDs and/or other KYC details, are requested to submit requisite request forms along with supporting documents to the Company's Registrar and Share Transfer Agent i.e., MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited), C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai – 400 083, Maharashtra, India. Tel : +91- 810 811 6767, e-mail ID: rnt.helpdesk@in.mpms.mufg.com
   - Shareholders who are holding shares in dematerialized mode and have not registered or updated their email IDs and/or other KYC details, are requested to register/ update the same along with any other pending KYC updation with their relevant depository participants.

   iv. The Finance Act, 2020 has abolished dividend distribution tax (DDT). Accordingly, effective from April 01, 2020; dividend income will be taxable in the hands of shareholders. Hence the Company is required to deduct tax at source ("TDS") from the amount of dividend paid to shareholders at the prescribed rates. The detailed TDS rates and required documents for claiming non-deduction/ lower deduction of TDS are uploaded on the website of the Company at: www.glandpharma.com

v. To avail the benefit of non-deduction/lower deduction of TDS, kindly submit the required documents by email on or before August 16, 2026, Or The forms/ documents (duly completed and signed) for claiming tax exemption are required to be uploaded on the URL: https://web.in.mpms.mufg.com/formsreg/submission-of-form-15g-5h.html - On this page the user shall be prompted to select / share the required information therein to register their request.

vi. The forms for tax exemption can be downloaded from MUFG Intime's website. The URL for the same is: https://web.in.mpms.mufg.com/client-downloads.html - On this page select the General tab. All the forms are available under the head "Form 15G/15H/10F".

vii. The upload of forms/documents (duly completed and signed) on the above mentioned URL of MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited) should be done on or before August 16, 2026, to enable the Company to determine and deduct appropriate TDS / Withholding Tax.

viii. Incomplete and/or unsigned forms and declarations will not be considered by the Company. No communication on the tax determination/ deduction shall be considered after August 16, 2026.

ix. In terms of the MCA and SEBI circular, in case the Company is unable to pay the dividend to any shareholder by electronic mode due to non availability of the details of their Bank Account, the Company will dispatch the Dividend Warrants / Demand drafts to such shareholders by post.

x. All Communications/ queries in this respect should be addressed to our RTA, MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited) to: investor.helpdesk@in.mpms.mufg.com

By Order of the Board of Directors

Sampath Kumar Pallerlamudi
Company Secretary
Membership No. A17901

Place: Hyderabad
Date: 15.06.2026

Registered Office Address:
Gland Pharma Limited
Survey No. 143-148, 150 & 151
Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal - Gandimaisamma Mandal
Medchal-Malkajgiri District
Hyderabad 500 043, Telangana, India
CIN: L24239TG1978PLC002276
Tel: 040-30510999, Fax:040-30510800
Email:gland@glandpharma.com
Website: https://glandpharma.com/